SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer, on April 21, 2016. The registrant is headquartered in Sydney, Australia, and files annual reports under Form 20-F. The filing serves to distribute an ASX Price Query Response (Exhibit 99.1) to the U.S. Securities and Exchange Commission.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing referencing an external response to a price query and contains no embedded financial statements or performance data.
Material Changes
No material changes versus a prior comparable period are disclosed in this filing. The document does not contain comparative financial data or operational updates.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the cover page and exhibit index for the ASX Price Query Response.
Key Facts for Investor Verification
- Verify the content of the attached "ASX Price Query Response" (Exhibit 99.1) to understand the specific market inquiry addressed.
- Confirm the company's current ticker symbol and trading status, as the filing references Prima BioMed Ltd while the request metadata mentions IMMUTEP Ltd.
- Review the company's most recent Form 20-F for actual financial performance data, as this Form 6-K contains none.